Vertex Pharmaceuticals (VRTX) Long-Term Debt Repayments (2013 - 2014)
Vertex Pharmaceuticals (VRTX) posted quarterly Long-Term Debt Repayments of -$140000.0 for Q4 2014, up 11.39% year-over-year from -$125681.8 in Q4 2013, and down 100.05% quarter-over-quarter from $294.4 million in Q3 2014.
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Long-Term Debt Repayments (2013 - 2014) Analysis & Trends
Vertex Pharmaceuticals' Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at -$140000.0 for Q4 2014.
- In Q4 2014, Long-Term Debt Repayments rose 11.39% year-over-year to -$140000.0; the TTM figure through Dec 2015 stood at $294.1 million (changed 0.0% YoY), while the FY2014 annual figure was $294.2 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q4 2014 stood at -$140000.0, down from $294.4 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $294.4 million in Q3 2014, with the low at -$158000.0 in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2014 | -140,000.00 |
| Sep 30, 2014 | 294.38 Mn |
| Dec 31, 2013 | -158,000.00 |